- Home
- ADPT vs GRAL Comparison
ADPT vs GRAL Comparison
Compare ADPT & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- GRAL
- Stock Information
- Founded
- ADPT 2009
- GRAL 2016
- Country
- ADPT United States
- GRAL United States
- Employees
- ADPT N/A
- GRAL N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- GRAL
- Sector
- ADPT Health Care
- GRAL
- Exchange
- ADPT Nasdaq
- GRAL NYSE
- Market Cap
- ADPT 1.4B
- GRAL 1.3B
- IPO Year
- ADPT 2019
- GRAL N/A
- Fundamental
- Price
- ADPT $11.48
- GRAL $47.56
- Analyst Decision
- ADPT Strong Buy
- GRAL Buy
- Analyst Count
- ADPT 7
- GRAL 3
- Target Price
- ADPT $10.57
- GRAL $31.50
- AVG Volume (30 Days)
- ADPT 2.2M
- GRAL 1.5M
- Earning Date
- ADPT 07-31-2025
- GRAL 08-12-2025
- Dividend Yield
- ADPT N/A
- GRAL N/A
- EPS Growth
- ADPT N/A
- GRAL N/A
- EPS
- ADPT N/A
- GRAL N/A
- Revenue
- ADPT $189,527,000.00
- GRAL $130,711,000.00
- Revenue This Year
- ADPT $24.46
- GRAL $19.52
- Revenue Next Year
- ADPT $20.25
- GRAL $20.37
- P/E Ratio
- ADPT N/A
- GRAL N/A
- Revenue Growth
- ADPT 8.61
- GRAL 30.47
- 52 Week Low
- ADPT $3.30
- GRAL $12.33
- 52 Week High
- ADPT $12.43
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- ADPT 63.39
- GRAL N/A
- Support Level
- ADPT $11.17
- GRAL N/A
- Resistance Level
- ADPT $12.43
- GRAL N/A
- Average True Range (ATR)
- ADPT 0.59
- GRAL 0.00
- MACD
- ADPT 0.03
- GRAL 0.00
- Stochastic Oscillator
- ADPT 62.45
- GRAL 0.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.